By: Christopher Parrella, Esq., CPC, CHC, CPCO
Parrella Health Law, Boston, MA.
A Health Care Provider Defense and Compliance Firm.

The Centers for Medicare & Medicaid Services and the Food and Drug Administration just announced a new pathway that could materially change how medical devices move from approval to reimbursement. The program, called RAPID, is designed to align FDA approval with Medicare coverage so that reimbursement can occur much closer to market entry.

That is the goal. The reality is more nuanced. For years, device manufacturers have faced a predictable problem. FDA approval determines whether a product is safe and effective, but Medicare makes a separate determination about whether it is “reasonable and necessary.” That gap has delayed reimbursement for years in some cases, even for breakthrough technologies. RAPID is an attempt to close that gap by aligning those processes earlier.

Under this model, device developers will engage with CMS during the FDA review process to determine what evidence is needed for coverage. If done correctly, that means a device could receive Medicare coverage shortly after FDA authorization, rather than waiting through a separate and often lengthy coverage process. That is a meaningful shift. But this is not automatic coverage and that is where providers need to focus.

CMS is not lowering its standards. It is moving the evidentiary burden earlier in the process. Developers will need to meet agreed-upon clinical endpoints, often through pivotal trials that include Medicare populations, to secure coverage. In other words, faster reimbursement is available, but only if the data is there. From a provider perspective, particularly those working with innovative technologies, this creates both opportunity and risk.

On the upside, this could accelerate access to new devices and treatments. If coverage decisions happen closer to FDA approval, providers may be able to adopt new technologies faster without the reimbursement uncertainty that has historically slowed adoption. On the downside, this model places more emphasis on clinical evidence that is directly relevant to Medicare beneficiaries. That is a different standard than what many device trials have historically focused on. Outcomes that matter to CMS, such as functional improvement or long-term value, may not align perfectly with endpoints used for FDA approval.

What Providers Should Do Now

If you are working with device companies, investing in new technologies or operating in environments where innovation drives care delivery, this is not something to watch passively. Understand what evidence is being generated. If a device is being positioned for RAPID, you need to know whether the clinical data will support Medicare coverage, not just FDA approval. Evaluate adoption risk. Faster approval does not guarantee reimbursement. Make sure your financial and operational models account for that. Engage early. Providers may have a role in clinical trials or data generation that ultimately determines coverage. That is where influence exists.

Bottom Line

CMS and FDA are trying to solve a real problem by aligning approval and reimbursement. That is a positive development, but it comes with a higher expectation around evidence. Faster coverage is coming. It just will not come easily. If you have any questions or comments about the subject of this blog, please contact Parrella Health Law at 857.328.0382 or Chris directly at cparrella@parrellahealthlaw.com.